Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cardiol
Main Authors: Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Periodicals, Inc. 2017
Assuntos:
Trial Designs
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396348/
https://ncbi.nlm.nih.gov/pubmed/28294373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22692
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados